Curaleaf Escalates Pressure on Aurora Board Over Stalled Acquisition

Curaleaf CEO Boris Jordan characterized the Aurora board’s refusal to engage in price discussions as a deliberate attempt to preserve management positions at the expense of investors. Curaleaf’s critique centers on Aurora’s long-running reliance on equity issuance to fund operations, noting that since 2020, the company has raised $398 million through share sales, resulting in 31% dilution. Curaleaf contends that Aurora’s own financial guidance forecasts declining revenue and EBITDA for 2027, undermining the board's argument that the company is better off independent.

Beyond the valuation gap, Curaleaf points to its own cash flow generation—$157 million over the last twelve months—as evidence of superior operational health. The company also addressed concerns regarding its own debt and tax structures, maintaining that its position is well-managed and backed by institutional lender confidence. For shareholders, the debate hinges on whether to bet on Aurora’s multi-year restructuring or accept a premium exit into a more diversified, cash-generative platform. Curaleaf maintains its offer remains open, urging Aurora investors to demand transparency regarding the board’s refusal to negotiate.